Key result
Higher fasting free fatty acids were inversely associated with incident hospitalized heart failure in patients with type 2 diabetes.
Why the study?
To examine whether circulating substrate mix relates to the incidence of HF and CV mortality and how it is altered by canagliflozin treatment.
Do fasting substrate concentrations predict incident heart failure and cardiovascular mortality in patients with type 2 diabetes?
RCT (n=3,581)
randomized
Do fasting substrate concentrations predict incident heart failure and cardiovascular mortality in patients with type 2 diabetes?
Higher baseline free fatty acids are associated with a lower risk of incident heart failure in patients with type 2 diabetes, suggesting a protective role of lipolysis that may be enhanced by canagliflozin.
Answers are grounded in this paper and cite their sources.
Higher fasting FFA linked to lower HF risk; hypothesis-generating for canagliflozin lipolysis effects on outcomes.
OBJECTIVE: To examine whether the circulating substrate mix may be related to the incidence of heart failure (HF) and cardiovascular (CV) mortality and how it is altered by canagliflozin treatment. RESEARCH DESIGN AND METHODS: We measured fasting glucose, free fatty acids (FFA), glycerol, β-hydroxybutyrate, acetoacetate, lactate, and pyruvate concentrations in 3,581 samples from the CANagliflozin cardioVascular Assessment Study (CANVAS) trial at baseline and at 1 and 2 years after randomization. Results were analyzed by univariate and multivariate Cox proportional hazards models. RESULTS: Patients in the lowest baseline FFA tertile were more often men with a longer duration of type 2 diabetes (T2D), higher urinary albumin excretion, lower HDL-cholesterol levels, higher history of CV disease (CVD), and higher use of statins and insulin. When all seven metabolites were used as predictors, FFA were inversely associated with incident hospitalized HF (hazard ratio [HR] 0.33 [95% CI 0.21-0.55]), while glycerol was a positive predictor (2.21 [1.45-3.35]). In a model further adjusted for 16 potential confounders, including prior HF and CVD and pharmacologic therapies, FFA remained a significant negative predictor. FFA and glycerol also predicted CV mortality (HR 0.53 [95% CI 0.35-0.81] and 1.81 [1.26-2.58], respectively) and all-cause death (0.50 [0.36-0.70] and 1.64 [1.22-2.18]). When added to these models, background insulin therapy was an independent positive predictor of risk of death. Canagliflozin treatment significantly increased plasma FFA and β-hydroxybutyrate regardless of background antihyperglycemic therapy. CONCLUSIONS: A constitutive metabolic setup consisting of higher lipolysis may be beneficial in delaying or preventing hospitalized HF; a further stimulation of lipolysis by canagliflozin may reinforce this influence.
No takes yet. Share an insight, caveat, or question.
Ferrannini et al. (2022) conducted an RCT in Type 2 diabetes (n=3,581). Fasting free fatty acids (FFA) was evaluated on incident hospitalized HF (HR 0.33, 95% CI 0.21-0.55). Higher fasting free fatty acids were inversely associated with incident hospitalized heart failure in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: